Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint Inhibitors

Cancer treatment has undergone a transformative shift with the advent of immune checkpoint inhibitors (ICIs). By targeting critical immune checkpoints like programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICIs unleash robust anti-tumor immune responses while disrupting mechanisms that maintain immune homeostasis. This review explores these checkpoint regulations, the distinct roles of various inhibitors in T-cell modulation, and their therapeutic implications. Clinical trials have demonstrated significant efficacy of ICIs across cancer types, yielding improved overall survival (OS), progression-free survival (PFS), and objective response rates (ORR) in specific patient subsets. Despite these successes, challenges such as primary and acquired resistance, immune-related adverse events, and biomarker identification remain. Factors like the tumor microenvironment (TME), tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and PD-L1 expression are under investigation to enhance therapeutic outcomes. This review also highlights emerging targets beyond PD-1, PD-L1, and CTLA-4, including LAG-3, TIM-3, TIGIT, and VISTA, alongside innovative combination strategies. Emphasis is placed on early detection and management of adverse events and the promise of personalized cancer immunotherapy. This comprehensive review aims to support clinicians and researchers in navigating the complexities of ICIs while advancing cancer immunotherapy strategies.